Company Announcements

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

Appointment of Non-Executive Directors

6 DECEMBER 2022: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents Southern Fox Investments Limited ("Southern Fox") and Simon represents ZQ Capital Management Limited ("ZQ Capital") acting through its affiliate SkyGem Acquisition Limited, both significant shareholders of the Company.

Anthony has worked in investment banking and fund management for over thirty years and, as Founder and Partner of Beagle Partners LLP, which advises Southern Fox, has managed or advised on multiple UK innovation technology investments. He is Founder and Chairman of Argonaute RNA Ltd, a UK-based research company developing safe and reliable methods of temporarily silencing target genes in different tissue cells. Prior to this, Anthony held senior roles at ING Barings and was an equity analyst for Cazenove & Co. He holds an Investment Management Certificate from the Institute of Investment Management and Research.

Simon founded the investment and advisory firm, ZQ Capital, in 2015. Prior to that he spent more than a decade as an investment banker advising international companies on their capital markets activities. He was Managing Director and Head of China Financial Institutions Group at Barclays from 2011 to 2015, following earlier roles at Goldman Sachs, Lehman Brothers and McKinsey & Company. He has a BA in mathematics and economics from Wesleyan University.

Peter Jensen, Non-Executive Chairman of Allergy Therapeutics, commented: "On behalf of the Board I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy over many years, and I have no doubt Anthony and Simon will be invaluable members of the Board, bringing extensive business and innovation sector experience."

Additional Disclosures

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules of Companies.

Mr Anthony Michael Parker (aged 60) holds, or has held, the following current and former directorships and partnerships in the past five years:

Mr Parker holds 275,000 ordinary shares in the capital of the Company. Mr Parker does not hold any options, rights to subscribe or other interests in such shares.

Mr Zheqing (Simon) Shen (aged 43) is, or has been, a director or partner of the following companies or partnerships during the past five years:

Mr Shen holds 90,000 ordinary shares in the capital of the Company. In addition, ZQ Capital, through its affiliate Skygem Acquisitions Limited holds 173,650,037 ordinary shares in the capital of the Company and also holds warrants over 16,666,666 ordinary shares. Mr Shen is managing partner and founder of ZQ Capital Mr Shen does not hold any other shares in the capital of the Company, nor any options, rights to subscribe or other interests in such shares.

Save as set out above, no further information regarding Anthony Parker or Zheqing (Simon) Shen is required to be disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott, David Daley, Davide Salvi

allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .